tiprankstipranks
Tiziana announces clinical improvements in second patient with non-active SPMS
The Fly

Tiziana announces clinical improvements in second patient with non-active SPMS

Tiziana Life Sciences announced that the second patient with non-active secondary progressive multiple sclerosis receiving intranasal foralumab has shown additional clinical improvements since their last reported improvement in September 2022. The improvements were measured by the Expanded Disability Status Scale, a U.S. Food and Drug Administration – recognized standard clinical outcome assessment that is a measure of neural network functioning, rating different measures from 1 to 10. Before foralumab treatment, EA2’s non-active SPMS disability had progressed and EDSS worsened from 3.5 in 2018 to 6.0 in 2021 despite ocrelizumab therapy. Ocrelizumab was discontinued in 2021. At this point, EA2 required a cane to walk 100 meters. EA2 was subsequently enrolled in the intranasal foralumab Expanded Access program in January 2022. In September 2022, 8 months after starting treatment with nasal foralumab, EA2 was able to walk 100 meters without a cane. EDSS score improved from 6.0 to 5.5. EA2’s pyramidal score remained stable during this time. In December 2022, 11 months after starting treatment with intranasal foralumab, EA2 was able to walk 200 meters without a cane, resulting in an even greater improvement in EDSS; with EDSS falling from a score of 5.5 to 5.0. EA2’s pyramidal score continued to remain stable.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on TLSA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles